This is for patients with surgical or medically castrated metastatic prostate cancer that is progressing following treatment with Zytiga, Xtandi, and taxane based chemotherapy.

Trial summary:
This trial is to determine how patients with progressive disease following treatment for metastatic castration-resistant prostate cancer will respond to treatment with the investigational agent rucaparib. Rucaparib is a PARP inhibitor that has been shown to kill cancer cells with certain genetic mutations or alterations.

Patients with tumors associated with BRCA1, BRCA2, or ATM gene mutations or alterations but will be placed in one arm if the presence of tumor spread beyond the prostate gland can be identified. Patients with BRCA1,BRCA2, or ATM genetic mutations or alterations will be placed in another arm if the presence of tumor spread beyond the prostate gland cannot be identified. A third study arm will include patients with tumors that are associated with other types of genetic mutations or alterations. 

Potential Patient Benefits: Increased survival in patients with metastatic hormone resistant prostate cancer.

Potential Patient Risks: Rucaparib will have no effect on tumor progression or extending survival. Side effects following use of rucaparib are also possible.

•  Use the "clinical trials glossary" or "dictionary" for words, phrases and treatments that you may not understand

• Register your interest or comments about this trial with PHEN

Organization:   Clovis Oncology, Inc.

Contact: Clovis Oncology Clinical Trial Navigation Service in the USA 1-855-262-3040; clovistrials@emergingmed.com

Clinicaltrials.gov link with study locations

* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.

Go Back